Market
Most significant risk reduction condition from GLP-1 drugs by end of 2025?
2
Resolution / Starting Odds
Heart attack • 25%
Dementia • 25%
Substance abuse • 25%
Schizophrenia • 25%
New study results published in peer-reviewed journals
Story
GLP-1 Drugs Like Ozempic, Wegovy Reduce Risk of 42 Conditions, Increase Risk of 19 Including Pancreatitis
Jan 20, 2025, 10:01 PM
A comprehensive study published in Nature Medicine has analyzed the health impacts of GLP-1 receptor agonists, such as Ozempic, Wegovy, and Mounjaro, on over 2 million diabetic patients. The research, conducted by scientists from Washington University and the Veterans Affairs St. Louis Health Care System, found that these drugs, primarily used for managing type 2 diabetes and obesity, are associated with a reduced risk of 42 health conditions. These include a 9% lower risk of heart attacks, an 8% reduced risk of dementia, and decreased risks of substance abuse, schizophrenia, and suicidal thoughts. However, the study also identified an increased risk for 19 conditions, including gastrointestinal issues, kidney stones, and a more than doubled risk of pancreatitis. The findings suggest that while GLP-1 agonists offer significant health benefits, they also come with notable risks that require careful monitoring.
View original story
Similar markets
Other • 25%
Stroke • 25%
Chronic Kidney Disease • 25%
Heart Disease • 25%
More risks • 25%
More benefits • 25%
Mixed findings • 25%
No significant new findings • 25%
Other • 25%
Alzheimer's Disease • 25%
Obesity • 25%
Type 2 Diabetes • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Obstructive Sleep Apnea • 25%
Other • 25%
Metabolic Liver Dysfunction • 25%
Alzheimer's Disease • 25%
50-69% reduction • 25%
70% or more reduction • 25%
25-49% reduction • 25%
Less than 25% reduction • 25%
Divided opinion • 25%
More favorable • 25%
Less favorable • 25%
No significant change • 25%
Other • 25%
Metabolic Liver Dysfunction • 25%
Diabetic Macular Edema • 25%
Addiction Treatment • 25%